ECOG or Karnofsky Performance Status to Assess Functionality in Glioblastoma Patients Among Different Observers

Panciroli, Claudia; Estival, Anna; Lucente, Giuseppe; Velarde, J.M.; García, Ricardo Hernández; Vilà, Laia; Domènech, Sira; Villà, Salvador; Balañá, Carmen

doi:10.4172/2155-9929.s2-032

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7,8 Of note, the PRODIGE/ACCORD trial enrolled a higher percentage of patients with good performance status [Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 in 38.0%, 1 in 61.7%, and 2 in 0.3% of patients] compared with the MPACT trial [Karnofsky performance status of 100 (equivalent to ECOG PS of 0) in 16%, 90/80 (equivalent to ECOG PS of 1) in 76%, and 70/60 (equivalent to ECOG PS of 2) in 8% of patients]. 6,7,9 In a recent phase II study assessing nab-P/G specifically in patients with poor performance status (ECOG PS of 2), the median OS in patients with advanced disease who received treatment at the same dose and schedule as in the MPACT trial was 8.7 months. 10 On the basis of these results, the current National Comprehensive Cancer Network and European Society for Medical Oncology guidelines recommend combination chemotherapy with nab-P/G or FOLFIRINOX as the preferred first-line treatments for patients with mPC who have good performance status.…”

Section: Introductionmentioning

confidence: 99%

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review

et al. 2019

View full text Add to dashboard Cite

Background: No clinical trial has directly compared nab-paclitaxel/gemcitabine (nab-P/G) with FOLFIRINOX (fluorouracil/leucovorin/oxaliplatin/irinotecan) in metastatic or advanced pancreatic cancer (mPC or aPC). We conducted a systematic review of real-world studies comparing these regimens in the first-line setting. Methods: Embase and MEDLINE databases through 22 January 2019, and Gastrointestinal Cancers Symposium 2019 abstracts were searched for real-world, retrospective studies comparing first-line nab-P/G versus FOLFIRINOX in mPC or aPC that met specific parameters. Studies with radiotherapy were excluded. Study quality was assessed using the Newcastle–Ottawa Scale. Results: Of 818 records initially identified, 35 were duplicates and 749 did not meet the eligibility criteria, mostly because they were either not comparative ( n = 356) or not first line ( n = 245). The remaining 34 studies (21 mPC; 13 aPC) assessed >6915 patients who received nab-P/G or FOLFIRINOX. In the studies identified, the median overall survival (OS) reached 14.4 and 15.9 months with nab-P/G and FOLFIRINOX, respectively, and median progression-free survival reached 8.5 and 11.7 months, respectively. Safety data were reported in 14 studies (2205 patients), including 8 single-institutional studies. In most single-institutional studies that reported safety data, rates were higher with FOLFIRINOX versus nab-P/G for grade 3/4 neutropenia (five of six studies) and febrile neutropenia (all three studies), while rates of grade 3/4 peripheral neuropathy were higher with nab-P/G in four of seven studies. Conclusions: Although FOLFIRINOX was associated with slightly longer median OS in more studies, the differences, when available, were not statistically significant. Therefore, a randomized, controlled trial is warranted. Toxicity profile differences represent key considerations for treatment decisions.

show abstract

Section: Introductionmentioning

confidence: 99%

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…2 Menurut Panciroli dkk, KPS sangat penting dalam keputusan tata laksana. 17 Semakin rendah KPS pasien, semakin terbatas tata laksana yang dapat diberikan. Perawatan selama di rumah sakit diharapkan dapat memperbaiki status fungsional penderita kanker dengan terapi yang diberikan.…”

Section: Pembahasanunclassified

Faktor-Faktor Yang Memengaruhi Status Performa Pasien Tumor Intrakranial Di Rsupn Dr. Cipto Mangunkusumo

Laila¹,

Andriani²,

Sofyan³

et al. 2019

View full text Add to dashboard Cite

FACTORS INFLUENCING PERFORMANCE STATUS IN PATIENTS WITH INTRACRANIAL TUMOR AT CIPTO MANGUNKUSUMO GENERAL HOSPITALABSTRACTIntroduction: Patients diagnosed with malignancy have a long course of illness from diagnosis to treatment. Assessment of performance status (PS) is essential to give an overview of therapeutic readiness and patient’s prognosis. Karnofsky Performance Scale is a PS assessment used widely in neurooncology patients. This instrument can assess functional impairment among patients. To this date, clinical factors in admission time that influences KPS in hospitalized intracranial tumor has not been researched.Aim: To get an overview of KPS in hospitalized intracranial patients in Cipto Mangunkusumo General Hospital and to investigate factors that influence.Methods: The design of this research was cohort retrospective. The research was done in Cipto Mangunkusumo General Hospital using secondary data in 2015-2016. The subjects of the research were patients with intracranial tumors. Demographic, clinical status in admission, pathological anatomy, and performance status data were acquired. The data were processed and presented descriptively and analytically. Independent predictors investigated using multivariate logistic regression.Results: There were 68 subjects obtained in this research. As much as 35 (51.5%) subject had primary intracranial tumor. As much as 58 (85.2%) subjects aged <60 years old. As much as 51 (76.5%) subjects had supratentorial tumor. Majority of subjects (70%) had KPS score <70. Subjects with primary tumor had more cranial nerve palsy (p=0.021) and hemiparesis (p=0.038). Decreased consciousness increased the risk of KPS score <70 by 5.2x in the time of admission.Discussion: Majority of subjects had KPS score <70. Decreased consciousness in the time of admission is an independent predictive factor that lowers KPS.Keywords: Karnofsky Performance Scale, intracranial tumor, neurooncology, risk factorsABSTRAKPendahuluan: Pasien keganasan memiliki perjalanan penyakit yang panjang mulai dari diagnosis hingga tata laksana. Kondisi pasien dapat sangat beragam, sehingga penting dilakukan pengkajian status performa untuk memberikan gambaran kesiapan terapi dan prognosisnya. Instrumen yang paling sering digunakan secara standar internasional adalah Karnofsky Performance Scale (KPS). Sejauh ini belum diketahui penggunaan KPS pada pasien tumor intrakranial, mengingat performa pasien yang tidak hanya disebabkan oleh keganasannya, namun juga kecacatan akibat dari lesinya.Tujuan: Mendapatkan gambaran KPS pasien tumor intrakranial serta faktor-faktor yang memengaruhinya.Metode: Penelitian kohort retrospektif terhadap pasien tumor intrakranial yang dirawat di RSUPN Dr. Cipto Mangunkusumo, Jakarta, pada tahun 2015-2016. Dilakukan pencatatan karakteristik demografik pasien, faktor klinis saat admisi, patologi anatomi, dan KPS. Data disajikan secara deskriptif dan analitik, faktor prediktor independen diinvestigasi menggunakan analisis multivariat regresi logistik.Hasil: Didapatkan 68 subjek dalam penelitian ini dengan proporsi tumor primer dan sekunder sebanyak 33 dan 35 orang. Subjek perempuan lebih banyak pada kelompok tumor primer dan lebih sedikit pada tumor sekunder. Mayoritas subjek berusia <60 tahun (85,2%), lokasi tumor di supratentorial (76,5%), dan KPS masuk <70 (69,2%). Subjek dengan penurunan kesadaran saat masuk perawatan akan cenderung memiliki KPS <70 (p=0,005) dibanding faktor-faktor klinis lainnya dengan risiko 5,2x menyebabkan status performa yang rendah tersebut saat admisi.Diskusi: Sebagian besar subjek memiliki nilai KPS <70. Penurunan kesadaran saat admisi merupakan faktor prediktif independen penurunan KPS.Kata kunci: Faktor risiko, Karnofsky Performance Scale, neuroonkologi, tumor intrakranial

show abstract

“…Adapun Eastern Cooperative Oncology Group (ECOG) Performance Scale digunakan juga untuk menilai status fungsional pasien tumor yang telah dilakukan penatalaksanaan terhadap tumornya. 4, [7][8][9][10][11] Penelitian tentang penilaian kualitas hidup dengan menggunakan EORTC QLQ-C30 dan EORTC QLQ-BN20 khususnya untuk tumor primer intrakranial masih sedikit, sehingga pedoman klinisi tentang hal ini terbatas. Untuk di Indonesia sendiri, penggunaan dua kuesioner tersebut secara bersamaan untuk penilaian kualitas hidup pada pasien tumor intrakranial belum pernah dilaporkan.…”

Section: Pendahuluanunclassified

“…Status performa subjek dikatakan baik jika nilai KPS >50 dan ECOG Performance Scale <2. [10][11][12] EORTC QLQ-C30 dan EORTC QLQ-BN20 memiliki nilai 1-4 pada masing-masing pertanyaan dengan interpretasi disesuaikan kondisi pasien. Pada EORTC QLQ-C30, terdiri dari tiga skala utama yaitu: skala fungsional (5 ranah), skala kualitas hidup (1 ranah), dan skala keluhan (9 ranah); sedangkan EORTC QLQ-BN20, hanya terdiri dari skala keluhan (11 ranah).…”

Section: Metodeunclassified

Penilaian Kualitas Hidup Eortc QLQ-C30 Dan Eortc QLQ-Bn20 Pada Pasien Tumor Primer Intrakranial Pascaterapi

Puspa

Wibisono

Ang

2018

View full text Add to dashboard Cite

QUALITY OF LIFE ASSESSMENT IN PRIMARY INTRACRANIAL TUMOR AFTER TREATMENT USING EORTC QLQ-C30 AND EORTC QLQ-BN20ABSTRACTIntroduction: Increasing number of surviving primary intracranial tumor patients in line with discovery of new treatment will increase the patient’s morbidity.This makes quality of life of patient need to be evaluated.Aims: Assessed quality of life in primary intracranial tumor patients post treatment using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) along with EORTC QLQ-Brain Cancer Module (EORTC QLQ-BN20).Methods: This was descriptive analytics-cross sectional study. Performed on primary intracranial tumor subjects during Desember 2017-January 2018 at neurology, neurosurgery, and radiotherapy outpatient Dr. Hasan Sadikin central general hospital Bandung. The obtained average value and the relationship between characteristics with quality of life were assessed using cross tabulation and analyzed with Statistical Package for Social Science (SPSS) version 24.0.Results: There were 42 subjects. Highest scale group based on EORTC QLQ-C30 was cognitive function of func- tional scale 81,4+30,2 and quality of life scale 68,3+19,7. Most symptom scale was pain 40,5+35,3. Whereas based onEORTC QLQ-BN20, most symptom was headache 49,2+37,7. Tumor location was factor that affects quality of life.Discussions: Subjects’ quality of life were good based on EORTC QLQ-C30 and EORTC QLQ-BN20. Results were accordance with some previous studies, but assessment has done before and after treatment. Evaluation quality of life should be made before and after treatment. This study only assessed subject after treatment in Outpatient Installation. For future, it is necessary to conduct cohort study for quality of life evaluation.Keywords: EORTC QLQ-BN20, EORTC QLQ-C30, primary intracranial tumor, quality of lifeABSTRAKPendahuluan: Meningkatnya jumlah pasien tumor primer intrakranial yang bertahan hidup sejalan dengan ditemu- kannya terapi baru akan meningkatkan morbiditas pasien. Hal ini membuat kualitas hidup pasien perlu dievaluasi.Tujuan: Menilai kualitas hidup pada pasien tumor primer intrakranial pascatindakan dengan menggunakan Euro- pean Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) bersamaan dengan EORTC QLQ-Brain Cancer Module (EORTC QLQ-BN20).Metode: Penelitian deskriptif analitik yang dilakukan secara potong lintang, dilakukan pada subjek tumor primer intrakranial selama Desember 2017-Januari 2018 di instalasi rawat jalan neurologi, bedah saraf, dan radioterapi RSUP Dr. Hasan Sadikin, Bandung. Uji statistik untuk menilai rerata nilai yang didapat serta hubungan karakteristik dan kualitas hidup dengan tabulasi silang, kemudian diolah dengan Statistical Package for Social Science (SPSS) versi 24.0.Hasil: Didapatkan 42 subjek. Kelompok skala paling tinggi berdasarkan EORTC QLQ-C30 adalah skala fungsional yaitu fungsi kognitif 81,4 + 30,2 dan skala kualitas hidup 68,3 + 19,7. Skala keluhan terbanyak nyeri 40,5+35,3. Sedang- kan berdasarkan EORTC QLQ-BN20, keluhan terbanyak nyeri kepala 49,2+37,7. Lokasi tumor merupakan faktor yang memengaruhi kualitas hidup.Diskusi: Kualitas hidup subjek penelitian baik berdasarkan EORTC QLQ-C30 dan EORTC QLQ-BN20. Hasil sesuai dengan beberapa penelitian sebelumnya, namun penilaian dilakukan sebelum dan setelah tindakan. Evaluasi adanya perubahan kualitas hidup seharusnya dilakukan sebelum dan setelah tindakan. Penelitian ini hanya menilai subjek setelah tindakan di instalasi rawat jalan. Untuk kedepannya, perlu dilakukan penelitian kohort untuk penilaian kualitas hidup.Kata kunci: EORTC QLQ-BN20, EORTC QLQ-C30, kualitas hidup, tumor primer intrakranial

show abstract

ECOG or Karnofsky Performance Status to Assess Functionality in Glioblastoma Patients Among Different Observers

Cited by 3 publications

References 0 publications

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review

Faktor-Faktor Yang Memengaruhi Status Performa Pasien Tumor Intrakranial Di Rsupn Dr. Cipto Mangunkusumo

Penilaian Kualitas Hidup Eortc QLQ-C30 Dan Eortc QLQ-Bn20 Pada Pasien Tumor Primer Intrakranial Pascaterapi

Contact Info

Product

Resources

About